TERAPIAS HORMONAIS: COMPROVAÇÃO CIENTÍFICA BASEADA EM EVIDÊNCIAS E O USO INDISCRIMINADO
DOI:
https://doi.org/10.56238/revgeov16n5-222Palavras-chave:
Hormonioterapia, Enfermagem, Uso IndiscriminadoResumo
Práticas envolvendo a manipulação de hormônios sexuais perduram durante gerações, gerando impactos positivos e negativos tanto na saúde física quanto na saúde mental. Este estudo tem como objetivo abordar as últimas evidências sobre o assunto na perspectiva de diferentes autores, para assim consolidar o que há de conhecimento mais atualizado em benefícios e o que é desfavorável. Trata-se de uma revisão integrativa realizada nas bases SCIELO, LILACS, PUBMED e BVS, incluindo artigos entre os anos de 2020 à 2025. Foram selecionados 85 estudos que apresentaram importante relevância ao tema. Conclui-se que a terapia hormonal quando utilizada para o tratamento de condições adversas à saúde, principalmente aquelas que envolvam perda de massa muscular e óssea, e com o devido acompanhamento do profissional de saúde especializado pode contribuir significativamente para a melhora da qualidade de vida. Da mesma forma, o uso dessas substâncias sem indicações clínicas pode acometer sérias consequências à nível sistêmico, em destaque nos sistemas, neurológico, cardíaco, hepático, renal e reprodutor.
Downloads
Referências
Devita VT, Jr, Rosenberg SA, Lawrence TS. Hellman, and Rosenberg’s cancer: Principles & practice of oncology. Filadélfia, PA, USA: Lippincott Williams and Wilkins; 2018.
Costanzo LS. Constanzo Fisiologia. Ltda EE, editor. 2018.
Pardini D. Terapia de reposição hormonal na menopausa. Arq Bras Endocrinol Metabol [Internet]. 2014;58(2):172–81. Available from: http://dx.doi.org/10.1590/0004-2730000003044
de Nazaré Nunes Alves MJ, dos Santos MR. Anabolizantes - Evidências científicas: riscos e benefícios. Manole, editor. 2022.
1. Nieschlag E, Nieschlag S. ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019;180(6):R201–12. Available from: http://dx.doi.org/10.1530/EJE-19-0071
2.
3. Cunha TS, Cunha NS, Moura MJCS, Marcondes FK. Esteróides anabólicos androgênicos e sua relação com a prática desportiva. Rev Bras Ci?ncias Farm?uticas [Internet]. 2004;40(2):165–79. Disponível em: http://dx.doi.org/10.1590/s1516-93322004000200005
4.
5. Rocha M, Aguiar F, Ramos H. O uso de esteroides androgénicos anabolizantes e outros suplementos ergogénicos – uma epidemia silenciosa. Rev Port Endocrinol Diabetes Metab [Internet]. 2014;9(2):98–105. Disponível em: http://dx.doi.org/10.1016/j.rpedm.2014.09.002
6.
7. Handa JR, Price RH. Encyclopedia of stress. Androgen Action. 2000;183–8.
8.
9. Wajchenberg BL, Lerario AC, Betti RTB. Tratado de endocrinologia clínica. Grupo Nacional Editorial (GEN); 2014.
10.
11. Hall JE, Guyton AC. Tratado de Fisiologia Médica. 12o ed. Elsevier Editora Ltda; 2011.
12.
13. Gartlehner G, Patel SV, Reddy S, Rains C, Schwimmer M, Kahwati L. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: Updated evidence report and systematic review for the US Preventive Services Task Force: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA [Internet]. 2022;328(17):1747–65. Disponível em: http://dx.doi.org/10.1001/jama.2022.18324
14.
15. Silva P de V, Paula LCA de, Silvestre AF, Silva JM da, Souza Filho PAC de, Seixas LC, et al. ASPECTOS FISIOPATOLÓGICOS E CLÍNICOS DA OSTEOPOROSE. Rev Foco [Internet]. 2024;17(7):e5685. Disponível em: http://dx.doi.org/10.54751/revistafoco.v17n7-080
16.
17. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol [Internet]. 2017;4(1):46–56. Disponível em: http://dx.doi.org/10.5152/eurjrheum.2016.048
18.
19. Peris P, Martínez-Ferrer A, Monegal A, Martínez de Osaba MJ, Alvarez L, Ros I, et al. Aetiology and clinical characteristics of male osteoporosis. Have they changed in the last few years? Clin Exp Rheumatol. 2008;26(4):582–8.
20.
21. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J [Internet]. 2007;83(982):509–17. Disponível em: http://dx.doi.org/10.1136/pgmj.2007.057505
22.
23. Aibar-Almazán A, Voltes-Martínez A, Castellote-Caballero Y, Afanador-Restrepo DF, Carcelén-Fraile MDC, López-Ruiz E. Current status of the diagnosis and management of osteoporosis. Int J Mol Sci [Internet]. 2022;23(16):9465. Disponível em: http://dx.doi.org/10.3390/ijms23169465
24.
25. Adejuyigbe B, Kallini J, Chiou D, Kallini JR. Osteoporosis: Molecular pathology, diagnostics, and therapeutics. Int J Mol Sci [Internet]. 2023;24(19):14583. Disponível em: http://dx.doi.org/10.3390/ijms241914583.
26.
27. Lemoine S, Figueres L, Bacchetta J, Frey S, Dubourg L. Calcium homeostasis and hyperparathyroidism: Nephrologic and endocrinologic points of view. Ann Endocrinol (Paris) [Internet]. 2022;83(4):237–43. Disponível em: http://dx.doi.org/10.1016/j.ando.2022.05.003.
28.
29. Mithal A, Bansal B, Kyer CS, Ebeling P. The Asia-pacific regional audit-epidemiology, costs, and burden of osteoporosis in India 2013: A report of international osteoporosis foundation. Indian J Endocrinol Metab [Internet]. 2014;18(4):449–54. Disponível em: http://dx.doi.org/10.4103/2230-8210.137485.
30.
31. Voulgaridou G, Papadopoulou SK, Detopoulou P, Tsoumana D, Giaginis C, Kondyli FS, et al. Vitamin D and calcium in osteoporosis, and the role of bone turnover markers: A narrative review of recent data from RCTs. Diseases [Internet]. 2023;11(1):29. Disponível em: http://dx.doi.org/10.3390/diseases11010029.
32.
33. Babić Leko M, Pleić N, Gunjača I, Zemunik T. Environmental factors that affect parathyroid hormone and calcitonin levels. Int J Mol Sci [Internet]. 2021;23(1):44. Disponível em: http://dx.doi.org/10.3390/ijms23010044.
34.
35. Costa ALD, Silva MACN da, Brito LMO, Nascimento ACB, Barbosa M do CL, Batista JE, et al. Osteoporose na atenção primária: uma oportunidade para abordar os fatores de risco. Rev Bras Reumatol [Internet]. 2016;56(2):111–6. Disponível em: http://dx.doi.org/10.1016/j.rbr.2015.03.004.
36.
37. Handforth C, D’Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. Calcif Tissue Int [Internet]. 2018;102(2):251–64. Disponível em: http://dx.doi.org/10.1007/s00223-017-0369-x.
38.
39. Qizi JGJ. Calcium metabolism and osteoporosis: The role of the endocrine system. 2025; Disponível em: http://dx.doi.org/10.5281/ZENODO.15070428.
40.
41. Tasnim N, Dutta P, Nayeem J, Masud P, Ferdousi A, Ghosh AS, et al. Osteoporosis, an inevitable circumstance of chronic kidney disease: A systematic review. Cureus [Internet]. 2021;13(10):e18488. Disponível em: http://dx.doi.org/10.7759/cureus.18488.
42.
43. Barnsley J, Buckland G, Chan PE, Ong A, Ramos AS, Baxter M, et al. Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res [Internet]. 2021;33(4):759–73. Disponível em: http://dx.doi.org/10.1007/s40520-021-01817-y.
44.
45. Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int [Internet]. 2016;27(1):367–76. Disponível em: http://dx.doi.org/10.1007/s00198-015-3386-5.
46.
47. Jeremiah MP, Unwin MDBK, Greenawald MH, Carilion VT. Diagnosis and management of osteoporosis [Internet]. Aafp.org. Disponível em: https://www.aafp.org/pubs/afp/issues/2015/0815/p261.pdf.
48.
49. Matsushima-Nishiwaki R, Yamada N, Hattori Y, Hosokawa Y, Tachi J, Hori T, et al. SERMs (selective estrogen receptor modulator), acting as estrogen receptor β agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway. PLoS One [Internet]. 2022;17(1):e0262485. Disponível em: http://dx.doi.org/10.1371/journal.pone.0262485.
50.
51. Gosset A, Pouillès J-M, Trémollieres F. Menopausal hormone therapy for the management of osteoporosis. Best Pract Res Clin Endocrinol Metab [Internet]. 2021;35(6):101551. Disponível em: http://dx.doi.org/10.1016/j.beem.2021.101551.
52.
53. Du Y, Xie B, Wang M, Zhong Y, Lv Z, Luo Y, et al. Roles of sex hormones in mediating the causal effect of vitamin D on osteoporosis: A two-step Mendelian randomization study. Front Endocrinol (Lausanne) [Internet]. 2023;14:1159241. Disponível em: http://dx.doi.org/10.3389/fendo.2023.1159241.
54.
55. Wiren KM, Zhang X-W, Olson DA, Turner RT, Iwaniec UT. Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes. Bone [Internet]. 2012;51(5):835–46. Disponível em: http://dx.doi.org/10.1016/j.bone.2012.08.111.
56.
57. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell [Internet]. 2007;130(5):811–23. Disponível em: http://dx.doi.org/10.1016/j.cell.2007.07.025.
58.
59. Mohamad N-V, Soelaiman I-N, Chin K-Y. A concise review of testosterone and bone health. Clin Interv Aging [Internet]. 2016;11:1317–24. Disponível em: http://dx.doi.org/10.2147/CIA.S115472.
60.
61. Araújo Júnior NLC de, Athanazio DA. Terapia de reposição hormonal e o câncer do endométrio. Cad Saude Publica [Internet]. 2007;23(11):2613–22. Disponível em: http://dx.doi.org/10.1590/s0102-311x2007001100009.
62.
63. Paramsothy P, Harlow SD, Nan B, Greendale GA, Santoro N, Crawford SL, et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause [Internet]. 2017;24(2):142–9. Disponível em: http://dx.doi.org/10.1097/GME.0000000000000736.
64.
65. Ko S-H, Kim H-S. Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women. Nutrients [Internet]. 2020;12(1):202. Disponível em: http://dx.doi.org/10.3390/nu12010202.
66.
67. Pan M, Pan X, Zhou J, Wang J, Qi Q, Wang L. Update on hormone therapy for the management of postmenopausal women. Biosci Trends [Internet]. 2022;16(1):46–57. Disponível em: http://dx.doi.org/10.5582/bst.2021.01418.
68.
69. Jeong HG, Park H. Metabolic disorders in menopause. Metabolites [Internet]. 2022;12(10):954. Disponível em: http://dx.doi.org/10.3390/metabo12100954.
70.
71. Okeke T, Anyaehie U, Ezenyeaku C. Premature menopause. Ann Med Health Sci Res [Internet]. 2013;3(1):90–5. Disponível em: http://dx.doi.org/10.4103/2141-9248.109458.
72. Rozenberg S, Vandromme J, Antoine C. Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol [Internet]. 2013 [citado 2 de novembro de 2025];9(4):216–27. Disponível em: https://www.nature.com/articles/nrendo.2013.17.
73.
74. Pardini D. Arq Bras Endocrinol Metabol [Internet]. 2014;58(2):172–81. Disponível em: http://dx.doi.org/10.1590/0004-2730000003044.
75.
76. Fonseca HP, Scapinelli A, Aoki T, Aldrighi JM. Rev Assoc Med Bras [Internet]. 2010;56(5):579–82. Disponível em: http://dx.doi.org/10.1590/s0104-42302010000500021.
77.
78. Kingsberg SA, Rezaee RL. Hypoactive sexual desire in women. Menopause [Internet]. 2013;20(12):1284–300. Disponível em: http://dx.doi.org/10.1097/GME.0000000000000131.
79.
80. Fernandes T, Costa-Paiva LH, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J Sex Med [Internet]. 2014;11(5):1262–70. Disponível em: http://dx.doi.org/10.1111/jsm.12473.
81.
82. Moreira MT, Correia Filho ÉC, Vidal LS, Guimarães LC, Tokarski LC, Baran MT, et al. Libido e menopausa: novas evidências para reposição de testosterona. Acervo Médico [Internet]. 2023;23(7):e13013. Disponível em: http://dx.doi.org/10.25248/reamed.e13013.2023.
83.
84. Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc [Internet]. 2017;92(1):114–28. Disponível em: http://dx.doi.org/10.1016/j.mayocp.2016.09.018.
85.
86. Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, et al. Global consensus Position Statement on the use of testosterone therapy for women. J Sex Med [Internet]. 2019;16(9):1331–7. Disponível em: http://dx.doi.org/10.1016/j.jsxm.2019.07.012.
87.
88. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril [Internet]. 2002;77(4):660–5. Disponível em: http://dx.doi.org/10.1016/s0015-0282(02)02969-2.
89.
90. Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab [Internet]. 2014;99(10):3489–510. Disponível em: http://dx.doi.org/10.1210/jc.2014-2260.
91.
92. Somboonporn W, Bell RJ, Davis SR. Testosterone for peri and postmenopausal women. Cochrane Libr [Internet]. 2005; Disponível em: http://dx.doi.org/10.1002/14651858.cd004509.pub2.
93.
94. Blümel JE, Del Pino M, Aprikian D, Vallejo S, Sarrá S, Castelo-Branco C. Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecol Endocrinol [Internet]. 2008;24(12):691–5. Disponível em: http://dx.doi.org/10.1080/09513590802454919.
95.
96. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab [Internet]. 2005;90(9):5226–33. Disponível em: http://dx.doi.org/10.1210/jc.2004-1747.
97. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol [Internet]. 2019;7(10):754–66. Disponível em: http://dx.doi.org/10.1016/S2213-8587(19)30189-5.
98.
99. Pašalić E, Tambuwala MM, Hromić-Jahjefendić A. Endometriosis: Classification, pathophysiology, and treatment options. Pathol Res Pract [Internet]. 2023;251(154847):154847. Disponível em: http://dx.doi.org/10.1016/j.prp.2023.154847.
Lv Q, Wang L, Luo X, Chen X. Adult stem cells in endometrial regeneration: Molecular insights and clinical applications. Mol Reprod Dev [Internet]. 2021;88(6):379–94. Disponível em: http://dx.doi.org/10.1002/mrd.23476.
Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol [Internet]. 2019;15(11):666–82. Disponível em: http://dx.doi.org/10.1038/s41574-019-0245-z.
Vannuccini S, Clemenza S, Rossi M, Petraglia F. Hormonal treatments for endometriosis: The endocrine background. Rev Endocr Metab Disord [Internet]. 2022;23(3):333–55. Disponível em: http://dx.doi.org/10.1007/s11154-021-09666-w.
Buck Louis GM, Hediger ML, Peterson CM, Croughan M, Sundaram R, Stanford J, et al. Incidence of endometriosis by study population and diagnostic method: the ENDO study. Fertil Steril [Internet]. 2011;96(2):360–5. Disponível em: http://dx.doi.org/10.1016/j.fertnstert.2011.05.087.
Patel BG, Lenk EE, Lebovic DI, Shu Y, Yu J, Taylor RN. Pathogenesis of endometriosis: Interaction between Endocrine and inflammatory pathways. Best Pract Res Clin Obstet Gynaecol [Internet]. 2018;50:50–60. Disponível em: http://dx.doi.org/10.1016/j.bpobgyn.2018.01.006.
Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril [Internet]. 2014;101(4):927–35. Disponível em: http://dx.doi.org/10.1016/j.fertnstert.2014.02.012.
Critchley HOD, Maybin JA, Armstrong GM, Williams ARW. Physiology of the endometrium and regulation of menstruation. Physiol Rev [Internet]. 2020;100(3):1149–79. Disponível em: http://dx.doi.org/10.1152/physrev.00031.2019.
Hudelist G, Valentin L, Saridogan E, Condous G, Malzoni M, Roman H, et al. What to choose and why to use - a critical review on the clinical relevance of rASRM, EFI and Enzian classifications of endometriosis. Facts Views Vis ObGyn [Internet]. 2021;13(4):331–8. Disponível em: http://dx.doi.org/10.52054/FVVO.13.4.041.
Keckstein J, Saridogan E, Ulrich UA, Sillem M, Oppelt P, Schweppe KW, et al. The Enzian classification: A comprehensive non-invasive and surgical description system for endometriosis. Acta Obstet Gynecol Scand [Internet]. 2021;100(7):1165–75. Disponível em: http://dx.doi.org/10.1111/aogs.14099.
Hernández Cardona MI, Ajewole C, Lewis H, Carrillo JF, Castellanos ME, Barish S, et al. Time to move beyond surgical classification systems for endometriosis. Int J Gynaecol Obstet [Internet]. 2023;163(1):58–62. Disponível em: http://dx.doi.org/10.1002/ijgo.14786.
Nogueira ACR, Santiago MT, Bahia C, Soares HP. Tratamento da endometriose pélvica: uma revisão sistemática. saude [Internet]. 2018 3(2):38–43. Disponível em: https://revista.unifagoc.edu.br/saude/article/view/368.
Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS. A clinician’s guide to the treatment of endometriosis with elagolix. J Womens Health (Larchmt) [Internet]. 2021;30(4):569–78. Disponível em: http://dx.doi.org/10.1089/jwh.2019.8096.
Lee J, Park HJ, Yi KW. Dienogest in endometriosis treatment: A narrative literature review. Clin Exp Reprod Med [Internet]. 2023;50(4):223–9. Disponível em: http://dx.doi.org/10.5653/cerm.2023.06128.
Albernaz Maia de Godoy Y, Campos Meneses A, Rodrigues Silva Filho D, Soares Leite M. Avanços no tratamento da endometriose: eficácia dos agonistas de GNRH no alívio da dor. Rev Bra de Edu e Saude [Internet]. 21º de outubro de 202; 13(4):744-53. Disponível em: https://www.gvaa.com.br/revista/index.php/REBES/article/view/10135.
Zajec V, Mikuš M, Vitale SG, D’alterio MN, Gregov M, Šarić MJ, et al. Current status and challenges of drug development for hormonal treatment of endometriosis: a systematic review of randomized control trials. Gynecol Endocrinol [Internet]. 2022;38(9):713–20. Disponível em: http://dx.doi.org/10.1080/09513590.2022.2109145.
da Costa Porto BT, Ribeiro PA, Kuteken F, Ohara F, Abdalla Ribeiro HS. Levonorgestrel intrauterine system versus dienogest effect on quality of life of women with deep endometriosis: a randomized open-label clinical trial. Women Health [Internet]. 2024;64(7):551–8. Disponível em: http://dx.doi.org/10.1080/03630242.2024.2382418.
Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood [Internet]. 2006;108(8):2509–19. Disponível em: http://dx.doi.org/10.1182/blood-2006-03-010777.
Onishi Y. Aplastic anemia: history and recent developments in diagnosis and treatment. Int J Hematol [Internet]. 2024;119(3):217–9. Disponível em: http://dx.doi.org/10.1007/s12185-024-03715-1.
Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell [Internet]. 2017;170(6):1079-1095.e20. Disponível em: http://dx.doi.org/10.1016/j.cell.2017.07.032.
Urbanowicz I, Nahaczewska W, Celuch B. Narrative review of aplastic anemia-the importance of supportive treatment. Ann Palliat Med [Internet]. 2021;10(1):694–9. Disponível em: http://dx.doi.org/10.21037/apm-20-1957.
Lee JW, Lee S-E, Jung CW, Park S, Keta H, Park SK, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol [Internet]. 2019;6(11):e562–72. Disponível em: http://dx.doi.org/10.1016/S2352-3026(19)30153-X.
Elmahdi S, Muramatsu H, Narita A, Ismael O, Hama A, Nishio N, et al. Markedly high plasma thrombopoietin (TPO) level is a predictor of poor response to immunosuppressive therapy in children with acquired severe aplastic anemia: TPO levels predict response to IST in childhood SAA. Pediatr Blood Cancer [Internet]. 2016;63(4):659–64. Disponível em: http://dx.doi.org/10.1002/pbc.25820.
Bereda G. Diagnosis, Pathophysiology and Management of Aplastic Anemia. TESS Res Med Clin. 28 de julho de 2022;1(1):102.
Liu L, Han B, Zhang Y, Lei M, Liu R, Lin Z, et al. First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study. Bone Marrow Transplant [Internet]. 2024;59(10):1449–57. Disponível em: http://dx.doi.org/10.1038/s41409-024-02377-1.
Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program [Internet]. 2012;2012(1):292–300. Disponível em: http://dx.doi.org/10.1182/asheducation.v2012.1.292.3798310
Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica [Internet]. 2009;94(5):712–9. Disponível em: http://dx.doi.org/10.3324/haematol.2008.002170.
Nassani M, Fakih RE, Passweg J, Cesaro S, Alzahrani H, Alahmari A, et al. The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes. Front Oncol [Internet]. 2023;13:1135160. Disponível em: http://dx.doi.org/10.3389/fonc.2023.1135160.
Pedro J, Santos B, Lacerda FB, Almeida De Oliveira L, Fialho BB, Assunção IN, et al. Neurological consequences of abusive use of anabolic-androgenic steroids [Internet]. Disponível em: https://www.mastereditora.com.br/periodico/20201004_094022.pdf.
Smit DL, Voogel AJ, den Heijer M, de Ronde W. Anabolic androgenic steroids induce reversible left ventricular hypertrophy and cardiac dysfunction. Echocardiography results of the HAARLEM study. Front Reprod Health [Internet]. 2021;3:732318. Disponível em: http://dx.doi.org/10.3389/frph.2021.732318.
Petrovic A, Vukadin S, Sikora R, Bojanic K, Smolic R, Plavec D, et al. Anabolic androgenic steroid-induced liver injury: An update. World J Gastroenterol [Internet]. 2022;28(26):3071–80. Disponível em: http://dx.doi.org/10.3748/wjg.v28.i26.3071.
Parente Filho SLA, Gomes PEA de C, Forte GA, Lima LLL, Silva Júnior GB da, Meneses GC, et al. Kidney disease associated with androgenic-anabolic steroids and vitamin supplements abuse: Be aware! Nefrología [Internet]. 2020;40(1):26–31. Disponível em: http://dx.doi.org/10.1016/j.nefro.2019.06.003.
Corona G, Rastrelli G, Marchiani S, Filippi S, Morelli A, Sarchielli E, et al. Consequences of anabolic-androgenic steroid abuse in males; Sexual and reproductive perspective. World J Mens Health [Internet]. 2022;40(2):165–78. Disponível em: http://dx.doi.org/10.5534/wjmh.210021.
Havnes IA, Jørstad ML, Innerdal I, Bjørnebekk A. Anabolic-androgenic steroid use among women - A qualitative study on experiences of masculinizing, gonadal and sexual effects. Int J Drug Policy [Internet]. 2021;95(102876):102876. Disponível em: http://dx.doi.org/10.1016/j.drugpo.2020.102876.
